Bank of America Reaffirms 'Buy' Rating for BioNTech Amid Strategic Shifts

Core Viewpoint - BioNTech (NASDAQ:BNTX) announced a strategic shift to establish an independent biotechnology company focused on next-generation mRNA technologies, while maintaining a strong focus on its oncology pipeline [2][3][7] Financial Performance - For the full year 2025, BioNTech reported revenues of €2.87 billion and an IFRS net loss of €1.136 billion (approximately $1.33 billion), compared to a loss of €665 million in 2024 [5][7] - The company ended 2025 with €17.2 billion in cash, cash equivalents, and security investments [5][7] - In Q4 2025, BioNTech posted an adjusted loss per share of approximately €0.33 (~38 cents in USD terms) [5] Strategic Developments - Co-founders Prof. Uur ahin and Prof. Özlem Türeci will lead the new biotechnology venture, with BioNTech contributing certain intellectual property rights and mRNA platform technologies in exchange for a minority equity stake, milestone payments, and royalties [2][3] - The transition is expected to be completed by the end of 2026, with binding agreements anticipated by mid-2026 [2][6] Market Reaction - Following the announcement, BioNTech shares fell as much as 21% in early trading, with recent quotes around $83, down approximately 18–19% from the previous close of $102.16 [4][7] - The stock fluctuated between a low of $79.52 and a high of $85.50, with trading volume exceeding 10.5 million shares [4] Analyst Rating - Bank of America Securities maintained a "Buy" rating on BioNTech, citing the company's strong cash position and progress towards becoming a multi-product oncology company, while lowering its price target to $128 from $134 [3][7]